Roxatidine
Histamine H2 antagonist, antiulcer and anti-inflammatory / A novel histamine H2 receptor antagonist.1 Suppresses inflammatory responses via inhibition of NFB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages.2 Clinically useful agent for prevention and healing of gastric and duodenal ulcers and bleeding.3 Attenuates degradation of extracellular matrix in osteoarthritis models by inactivating the NFkB pathway.4
Biochemicals & reagents
78273-80-0
1) Mills and Wood (1989), The pharmacology of histamine H2-receptor antagonists; Methods Find. Exp. Clin. Phamracol., 11 Suppl. 1 87 2) Cho et al. (2011), Roxatidine suppresses inflammatory responses via inhibition of NF-?B and p38 MAPK activation in LPS-induced RAW 264.7 macropages; J. Cell. Biochem., 112 3648 3) Imaeda et al. (2011), Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic sunmucosal dissection for superficial gastric neoplasia; J. Gastroenterol., 46 1267 4) Ze et al. (2017), Roxatidine Attenuates Degradation of Extracellular Matrix; Biomed. Pharmacother., 95 1156
-20°C
TARGET: GPCR -- PATHWAY: Histamine; NFkappaB; MAPK -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Inflammation